How the FDA's new mechanism guidelines may affect developing personalized gene editing treatments

The paper argues that the FDA's plausible mechanism framework may help advance personalized in vivo prime editing for ultra-rare liver-centered genetic disorders.

This is a regulatory and proof-of-concept report describing early customizable prime editing studies for 7 urea cycle disorders and a formal FDA meeting about an umbrella-of-umbrellas trial.

The abstract reports platform support and regulatory discussion, not clinical efficacy or safety outcomes in patients.